DKSH has expanded its partnership with Glenmark, a global pharmaceutical firm, to offer a wide range of its products focusing on dermatology, respiratory, and women health in Malaysia. Following the successful partnership in Cambodia and Vietnam, DKSH will leverage its expertise and global experience to enhance Glenmark’s business in Malaysia.
Petaling Jaya, March 18, 2024 – DKSH Business Unit Healthcare, a leading partner for companies seeking to grow their healthcare business in Asia and beyond, is proud to announce their strategic partnership with Glenmark Pharmaceuticals (M) Sdn Bhd, (Glenmark), a wholly owned subsidiary of Glenmark Pharmaceuticals Ltd., a research-based, global pharmaceutical company. This marks the third partnership between DKSH and Glenmark, following their initial collaboration in Cambodia and Vietnam.
Under this expanded partnership, DKSH Malaysia will oversee logistics operations for Glenmark’s wide range of high-quality products focusing on dermatology, respiratory and women’s health. By leveraging DKSH’s comprehensive industry experience combined with its insights into the local market and its robust network of partners, Glenmark’s products will be accessible to the Malaysian population. Hence, DKSH’s expertise in logistics and distribution will ensure efficient and timely distribution of Glenmark’s products to pharmacies, hospitals, and healthcare providers across Malaysia.
Tomas Mihal, Vice President and Regional Business Head Asia Pacific, Glenmark Pharmaceuticals Ltd. shared his enthusiasm about the recent collaboration, stating: “In our pursuit of pioneering a ‘New Way for a New World’ through science and innovation, we recognize DKSH as the ideal partner to expand Glenmark’s product range in Malaysia. This collaboration inspires us to continue to develop and provide access to groundbreaking therapies for the patients.”
Sandeep Tewari, Head Country Management and Vice President, Healthcare, DKSH Malaysia, added: “The expansion of partnership with Glenmark underscores our shared commitment to providing healthcare for all through innovation and excellence. Together, we aim to achieve new milestones and unlock exciting opportunities, and we look forward to seeing the positive impact it will have on Malaysian patients.”
The collaboration with Glenmark represents one of the pivotal strategic partnerships entered into by DKSH Healthcare this year in Malaysia, reinforcing DKSH’s role as the leading strategic healthcare solutions partner, furthering its commitment to enriching people’s lives by helping provide healthcare for all.
About Glenmark Pharmaceuticals Ltd.
Glenmark Pharmaceuticals Limited (BSE: 532296 | NSE: GLENMARK) is a research-led, global pharmaceutical company, having a presence across Branded, Generics, and OTC segments; with a focus on therapeutic areas of respiratory, dermatology and oncology. The company has 10 world-class manufacturing facilities spread across 4 continents, and operations in over 80 countries. In Vivo/Scrip 100 positions Glenmark amongst the Top 100 Companies Ranked by R&D and Pharmaceutical Sales, 2022; while Generics Bulletin/In Vivo places it in the Top 50 Generics and Biosimilars Companies Ranked by Sales, 2022. Glenmark’s Green House Gas (GHG) emission reduction targets have been approved in 2023 by the Science Based Target initiative (SBTi), making it only the second pharmaceutical company in India to achieve this. The organization has impacted over 3 million lives over the last decade through its CSR interventions. For more information, visit www.glenmarkpharma.com
About DKSH
DKSH’s purpose is to enrich people’s lives. For almost 160 years, DKSH has been delivering growth for companies in Asia and beyond across its Business Units Healthcare, Consumer Goods, Performance Materials, and Technology. As a leading Market Expansion Services provider, DKSH offers sourcing, market insights, marketing and sales, eCommerce, distribution and logistics as well as after-sales ser-vices. DKSH is a participant of the United Nations Global Compact and adheres to its principles-based approach to responsible business. Listed on the SIX Swiss Exchange, DKSH operates in 36 markets with 29,040 specialists, generating net sales of CHF 11.1 billion in 2023. DKSH Healthcare distributes pharmaceuticals, consumer health, and over-the-counter products as well as medical devices. With around 8,140 specialists, DKSH Healthcare generated net sales of CHF 5.6 billion in 2023. www.dksh.com/hec